©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Ophthalmol. May 12, 2013; 3(2): 16-19
Published online May 12, 2013. doi: 10.5318/wjo.v3.i2.16
Published online May 12, 2013. doi: 10.5318/wjo.v3.i2.16
Topical biological agents targeting cytokines for the treatment of dry eye disease
Kyung Chul Yoon, Department of Ophthalmology, Chonnam National University Medical School and Hospital, Gwangju 501-757, South Korea
Author contributions: Yoon KC solely contributed to this paper.
Supported by The Chonnam Natinal University Hospital Biomedical Research Institute (CRI 11076-21 and 13906-22); Forest Science and Technology Projects, No. S121313L050100, provided by Korea Forest Service
Correspondence to: Kyung Chul Yoon, MD, PhD, Department of Ophthalmology, Chonnam National University Medical School and Hospital, 8 Hak-Dong, Dong-Gu, Gwangju 501-757, South Korea. kcyoon@jnu.ac.kr
Telephone: +82-62-2206741 Fax: +82-62-2271642
Received: March 22, 2013
Revised: April 26, 2013
Accepted: May 10, 2013
Published online: May 12, 2013
Processing time: 66 Days and 23 Hours
Revised: April 26, 2013
Accepted: May 10, 2013
Published online: May 12, 2013
Processing time: 66 Days and 23 Hours
Core Tip
Core tip: Although the debate remains about the efficacy of systemic biological agents on Sjögren’s syndrome, topical biological agents targeting inflammatory cytokines can be applicable for the treatment of dry eye disease.